Wegovy Expands Beyond Weight Loss: China Approves Drug for Liver Disease, Pill Format Surges

Impossibile aggiungere al carrello

Puoi avere soltanto 50 titoli nel carrello per il checkout.

Riprova più tardi

Rimozione dalla Lista desideri non riuscita.

Riprova più tardi

Non è stato possibile aggiungere il titolo alla Libreria

Per favore riprova

Non è stato possibile seguire il Podcast

Per favore riprova

Esecuzione del comando Non seguire più non riuscita

Wegovy Expands Beyond Weight Loss: China Approves Drug for Liver Disease, Pill Format Surges

Ascolta gratuitamente

Vedi i dettagli del titolo

# Wegovy's Global Transformation: From Weight Loss Drug to Cardiometabolic Powerhouse **Episode Description:** Wegovy is no longer just a weight loss headline—it's reshaping global healthcare in real time. In this episode, we break down the major developments transforming how the world sees Novo Nordisk's blockbuster drug, from Beijing boardrooms to pediatric clinics in the United States. This week, we explore: 🔹 **China's landmark approval** — Wegovy becomes the first GLP-1 receptor agonist cleared to treat MASH (metabolic dysfunction-associated steatohepatitis), a severe liver condition, opening doors in one of the world's largest healthcare markets 🔹 **The obesity drug wars heat up** — Eli Lilly captures 30%+ of new U.S. oral obesity drug patients, forcing Novo Nordisk CEO Mike Doustdar to respond with a higher-dose Wegovy 7.2mg injectable 🔹 **Record-breaking pill launch** — The Wegovy oral tablet reportedly hits 5 million prescriptions in just six months, with Novo claiming 9 out of 10 pill-seeking patients choose their product over competitors 🔹 **European expansion** — Wegovy tablets roll out in Germany, offering needle-free alternatives amid supply chain pressures 🔹 **Milan data drop** — Preview of upcoming EASD conference presentations, including the Octane real-world study and next-gen combination drug CagriSema 🔹 **Childhood obesity breakthrough (and ethical debate)** — Step Young trial results show promising outcomes for children ages 6-11, but regulators haven't approved use in this age group yet 🔹 **Emerging safety signals** — New research links GLP-1 drugs like Wegovy, Ozempic, and Zepbound to a modest increased hair loss risk in genetically susceptible men 🔹 **Corporate rebrand** — Novo Nordisk simplifies to "Novo" in a strategic br Some great Deals https://amzn.to/49SJ3Qs For more check out http://www.quietplease.ai

Ancora nessuna recensione